FCCC LOGO Faculty Publications
Jain A , Ryan PD , Seiden MV
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location
J Natl Compr Canc Netw. 2012 Sep 1;10(9) :1076-80
PMID: 22956806   
Back to previous list
Approximately 22,000 cases of ovarian cancer occur each year in the United States, and likely fewer than 2000 cases of mucinous ovarian cancers. Although 90% of patients with mucinous ovarian cancer present with stage I disease and have curative surgeries, advanced-stage disease is known to have a poor response to standard platinum- and taxane-based chemotherapy. Despite limited enthusiasm, standard chemotherapy is still recommended for most patients with advanced-stage mucinous malignancies of the ovary. This report presents an unusual case of a woman with HER2-positive metastatic mucinous carcinoma of the ovary treated with chemotherapy regimens typically used for colorectal malignancies, followed by epidermal growth factor receptor-targeted therapies.
Jain, Angela Ryan, Paula D Seiden, Michael V United States Journal of the National Comprehensive Cancer Network : JNCCN J Natl Compr Canc Netw. 2012 Sep 1;10(9):1076-80.